1AYTWu, KongNCT, De LeonF, etal. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients the Micro Albuminuria Prevalence (MAP) Study[J]. Diabetologia, 2005, 48(1): 17-26.
2Carroll MC. The complement system in regulation of adaptive immunity [J]. Nature Immunology, 2004, 5 (10): 981-986.
4Vorup-Jensen T, Jensenius JC, Thiel S. MASP-2, the C3convertase generating protease of the MBL Lectin complement-activating pathway [J]. Immunobiology, 1998, 199(2): 348-357.
5Niculescu F, Rus H. The role of complement activation inatherosclerosis[J]. Immunol Res, 2004, 30(1): 73- 80.
6Niculescu F, Rus H. Mechanisms of signal transduc- tion activated by sub lytic assembly of terminal comple- ment complexes onnucleated cells [J]. Immunol Res, 2001, 24(2): 191-199.
7Turner MW. The role of mannose binding lectin in health and diseaselJ]. Mol Immunol, 2003, 40(7): 423-429.
9Ehrnthaller C, Ignatius A, Gebhard F, et al. New insights of an old defense system: structure, function, and clinical relevance of the complement system [J]. MolMed, 2011, 17: 317-329.
10Uesugi N, Sakata N, Nangaku M, et al. Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: Glycoxidation-mediated local complement activation [J]. Am J Kidney Dis, 2004, 44: 224-238.
